Business Description
Ipca Laboratories Ltd
ISIN : INE571A01038
Total Employee Number:
23,236Compare
Compare
Traded in other countries / regions
524494.India Index Membership
NIFTY 500 IPO Date
1995-02-08Description
Ipca Laboratories Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company is an integrated pharmaceutical company manufacturing and marketing over 350 formulations and various API's covering various therapeutic segments. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), and Losartan. The company has only one reportable primary business segment, pharmaceuticals. Geographically, the maximum revenue is derived from outside India, mainly from Europe, Africa, the Americas, Asia, etc.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.48 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.39 | |||||
Interest Coverage | 20.55 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 12.16 | |||||
Beneish M-Score | -2.4 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.5 | |||||
3-Year EBITDA Growth Rate | 25.2 | |||||
3-Year EPS without NRI Growth Rate | 36.2 | |||||
3-Year FCF Growth Rate | 16 | |||||
3-Year Book Growth Rate | 11.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.44 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.69 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.36 | |||||
9-Day RSI | 50.15 | |||||
14-Day RSI | 56.46 | |||||
3-1 Month Momentum % | 6.86 | |||||
6-1 Month Momentum % | 7.52 | |||||
12-1 Month Momentum % | 9.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.76 | |||||
Quick Ratio | 1.58 | |||||
Cash Ratio | 0.52 | |||||
Days Inventory | 336.51 | |||||
Days Sales Outstanding | 75.37 | |||||
Days Payable | 112.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.11 | |||||
Dividend Payout Ratio | 0.04 | |||||
3-Year Dividend Growth Rate | -20.6 | |||||
Forward Dividend Yield % | 0.33 | |||||
5-Year Yield-on-Cost % | 0.06 | |||||
Shareholder Yield % | 0.62 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.74 | |||||
Operating Margin % | 16.18 | |||||
Net Margin % | 11.83 | |||||
EBITDA Margin % | 21.42 | |||||
FCF Margin % | 5.04 | |||||
OCF Margin % | 11.84 | |||||
ROE % | 15.26 | |||||
ROA % | 9.41 | |||||
ROIC % | 12.13 | |||||
3-Year ROIIC % | 18.78 | |||||
ROC (Joel Greenblatt) % | 19.75 | |||||
ROCE % | 16.96 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 39.6 | |||||
Forward PE Ratio | 32.64 | |||||
PE Ratio without NRI | 37.95 | |||||
Shiller PE Ratio | 54.3 | |||||
Price-to-Owner-Earnings | 47.09 | |||||
PEG Ratio | 6.54 | |||||
PS Ratio | 4.69 | |||||
PB Ratio | 5.61 | |||||
Price-to-Tangible-Book | 5.75 | |||||
Price-to-Free-Cash-Flow | 92.98 | |||||
Price-to-Operating-Cash-Flow | 39.57 | |||||
EV-to-EBIT | 28.17 | |||||
EV-to-EBITDA | 22.46 | |||||
EV-to-Revenue | 4.81 | |||||
EV-to-FCF | 97.8 | |||||
Price-to-GF-Value | 1.12 | |||||
Price-to-Projected-FCF | 3.42 | |||||
Price-to-DCF (Earnings Based) | 1.6 | |||||
Price-to-DCF (FCF Based) | 8.27 | |||||
Price-to-Peter-Lynch-Fair-Value | 6.1 | |||||
Price-to-Graham-Number | 3.11 | |||||
| Price-to-Net-Current-Asset-Value | 21.83 | |||||
Earnings Yield (Greenblatt) % | 3.55 | |||||
FCF Yield % | 1.08 | |||||
Forward Rate of Return (Yacktman) % | 6.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ipca Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 96,463.3 | ||
| EPS (TTM) (₹) | 44.98 | ||
| Beta | 0.1807 | ||
| 3-Year Sharpe Ratio | 0.91 | ||
| 3-Year Sortino Ratio | 1.61 | ||
| Volatility % | 22.89 | ||
| 14-Day RSI | 56.46 | ||
| 14-Day ATR (₹) | 59.111564 | ||
| 20-Day SMA (₹) | 1771.715 | ||
| 12-1 Month Momentum % | 9.39 | ||
| 52-Week Range (₹) | 1251.6 - 1944.9 | ||
| Shares Outstanding (Mil) | 253.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ipca Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ipca Laboratories Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-13 16:00 | In 114 days | ||
| Second quarter earnings results for 2027 | 2026-11-13 | In 113 days | ||
| First quarter earnings conference call for 2027 | 2026-08-12 15:30 | In 21 days | ||
| First quarter earnings results for 2027 | 2026-08-12 | In 20 days | ||
| General meeting for 2026 | 2026-08-11 15:30 | In 20 days | ||
| INR 6.000000 Cash Dividend | 2026-08-07 | In 15 days | ||
| Annual report for 2026 | 2026-07-14 | 1,823.30 (+1.98%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-06-01 15:30 | 1,524.40 (-3.33%) | ||
| Fourth quarter earnings results for 2026 | 2026-06-01 | 1,524.40 (-3.33%) | ||
| Third quarter earnings conference call for 2026 | 2026-02-16 15:30 | 1,485.40 (+1.88%) |
Show
Entries
Ipca Laboratories Ltd Frequently Asked Questions
What is Ipca Laboratories Ltd(NSE:IPCALAB)'s stock price today?
The current price of NSE:IPCALAB is ₹1788.50. The 52 week high of NSE:IPCALAB is ₹1944.90 and 52 week low is ₹1251.60.
When is next earnings date of Ipca Laboratories Ltd(NSE:IPCALAB)?
The next earnings date of Ipca Laboratories Ltd(NSE:IPCALAB) is 2026-08-12 Est..
Does Ipca Laboratories Ltd(NSE:IPCALAB) pay dividends? If so, how much?
The Dividend Yield %  of Ipca Laboratories Ltd(NSE:IPCALAB) is 0.11% (As of Today), Highest Dividend Payout Ratio of Ipca Laboratories Ltd(NSE:IPCALAB) was 0.22. The lowest was 0.03. And the median was 0.09. The  Forward Dividend Yield % of Ipca Laboratories Ltd(NSE:IPCALAB) is 0.33%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Ipca Laboratories Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers